Clinical Trials Logo

Clinical Trial Summary

To confirm safety and pharmacokinetics of maraviroc following a single oral dose of 300 mg maraviroc in healthy male Japanese volunteers.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label


Related Conditions & MeSH terms


NCT number NCT00821535
Study type Interventional
Source ViiV Healthcare
Contact
Status Completed
Phase Phase 1
Start date February 2009
Completion date May 2009

See also
  Status Clinical Trial Phase
Completed NCT02715700 - Effects of Doravirine (MK-1439) on Methadone Pharmacokinetics in Methadone-Maintained Participants (MK-1439-045) Phase 1
Completed NCT03667547 - Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851) Phase 4
Completed NCT01422330 - A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients Phase 4
Active, not recruiting NCT05452616 - Same-day Versus Rapid ART Initiation in HIV-positive Individuals Presenting With Symptoms of Tuberculosis N/A
Completed NCT04515641 - Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030) Phase 1
Not yet recruiting NCT06430905 - Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART Phase 1
Terminated NCT02818283 - Soy Modulation of Immune Activation, LDL- Levels, and Lowering Inflammation by Pretzel Isoflavone Dietary Intervention N/A
Completed NCT04303156 - Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026) Phase 1
Completed NCT00717067 - Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function Phase 4
Recruiting NCT04375800 - Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Ages 4 Weeks to <12 Years and <45 kg (MK-1439-066) Phase 2
Completed NCT03618511 - Interventions to Improve HIV Antiretroviral Therapy Adherence N/A
Completed NCT01768182 - Folinic Acid and Vascular Reactivity in HIV N/A